BlackRock Virginia Municipal Bond Trust (BHV) Stock Price

10.21 ▼ -0.10 (-0.97%)
Open: 10.20 Vol: 1.4K Day's range: 10.20 - 10.21 Jun 13, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
BHV Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 10.18▲ 10.18▲ 10.18▲ 10.25▼ 10.24▼
MA10 10.78▼ 10.78▼ 10.78▼ 10.24▼ 10.30▼
MA20 10.67▼ 10.67▼ 10.67▼ 10.27▼ 10.58▼
MA50 10.82▼ 10.83▼ 10.85▼ 10.35▼ 10.96▼
MA100 11.05▼ 11.04▼ 11.01▼ 10.61▼ 10.73▼
MA200 10.88▼ 10.78▼ 10.71▼ 10.94▼ 12.47▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.075▼ -0.074▼ -0.074▼ 0.008▲ -0.028▼
RSI 46.566▼ 46.564▼ 46.559▼ 44.520▼ 34.653▼
STOCH 2.344▼ 2.344▼ 2.344▼ 33.007     20.131    
WILL %R -97.897▼ -97.897▼ -97.897▼ -70.732     -87.234▼
CCI -42.192     -42.192     -42.192     -45.622     -72.066    
Latest Filters Detected On BHV
RSI $BHV RSI(14) Crossed Below 50 Set Alert
MA $BHV Price Crossed Below MA(26) Set Alert
MA $BHV Price Crossed Below MA(13) Set Alert
MA $BHV Price Crossed Below MA(7) Set Alert
CDL $BHV Doji Candlestick Pattern Detected Set Alert
BlackRock Virginia Municipal Bond Trust News
BlackRock Virginia Municipal Bond Trust (BHV)
Wednesday, June 11, 2025 10:53 AM
Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated ...
Biohaven initiates Phase II/III trial of BHV-8000 for early Parkinson’s
Friday, May 30, 2025 11:54 AM
Biohaven has commenced a randomised Phase II/III trial of the tyrosine kinase 2 (TYK2) / Janus Kinase 1 (JAK1) inhibitor, BHV-8000, aimed at treating early Parkinson's disease (PD). The global ...
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
Thursday, May 29, 2025 04:01 AM
BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune ...
BHV historical stock data
date open high low close volume
13/06/25 10.20 10.21 10.20 10.21 1,400
12/06/25 10.35 10.35 10.31 10.31 900
11/06/25 10.29 10.36 10.22 10.29 1,200
09/06/25 10.19 10.22 10.19 10.22 600
06/06/25 10.30 10.30 10.19 10.20 1,200
05/06/25 10.33 10.33 10.21 10.21 600
04/06/25 10.14 10.24 10.14 10.18 2,800
03/06/25 10.27 10.49 10.1407 10.28 16,892
02/06/25 10.35 10.35 10.20 10.2703 4,599
30/05/25 10.3215 10.3215 10.1776 10.259 2,739
Quote Details
52wk Low:10.09
52wk High:11.76
Vol:1.4K
Avg Vol(3m):75.8K
1Y Chng:-7.43%
1M Chng:-1.16%
Add to Watch List
More Information
Index N/A
Market Cap. 16.34M